CTLA-4 directly inhibits osteoclast formation

Annals of the Rheumatic Diseases
R AxmannG Schett

Abstract

CTLA-4 is a regulator of co-stimulation and inhibits the activation of T cells through interfering with the interaction of CD80/86 on antigen-presenting cells with CD28 on T cells. CTLA-4 binds to the surface of antigen-presenting cells, such as dendritic cells and monocytes through CD80/86. Monocytes can differentiate in osteoclasts, the primary bone resorbing cells. Herein, we investigated whether the binding of CTLA-4 affects the differentiation of monocytes into osteoclasts in vitro and vivo. We show that CTLA-4 dose-dependently inhibits RANKL- as well as tumour necrosis factor (TNF)-mediated osteoclastogenesis in vitro without the presence of T cells. Furthermore, CTLA-4 was effective in inhibiting TNF-induced osteoclast formation in a non-T cell dependent TNF-induced model of arthritis as well as the formation of inflammatory bone erosion in vivo. These data suggest that CTLA-4 is an anti-osteoclastogenic molecule that directly binds osteoclast precursor cells and inhibits their differentiation. These findings are an attractive explanation for the anti-erosive effect of abatacept, a CTLA-4 immunoglobulin fusion protein used for the treatment of rheumatoid arthritis.

Citations

Jun 17, 2010·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·C Roux
Oct 21, 2010·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·C B Confavreux, R D Chapurlat
Jun 19, 2013·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·M VisW F Lems
Aug 18, 2010·Wiener medizinische Wochenschrift·Reinhard Gruber
Feb 3, 2009·Immunologic Research·Kofi A MensahEdward M Schwarz
Nov 4, 2010·Nature Reviews. Endocrinology·Georg Schett, Jean-Pierre David
Sep 26, 2012·Nature Reviews. Rheumatology·Georg Schett, Ellen Gravallese
Mar 14, 2012·Nature Reviews. Rheumatology·Josef S SmolenKurt Redlich
Apr 4, 2009·Current Opinion in Rheumatology·Vincent GoëbPaul Emery
Jul 9, 2011·The Journal of Clinical Investigation·Dallas JonesAntonios O Aliprantis
Feb 24, 2009·Arthritis Research & Therapy·Georg Schett
Aug 25, 2011·Arthritis Research & Therapy·Baohong Zhao, Lionel B Ivashkiv
Feb 16, 2011·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Yuka YasuokaTaku Seriu
Jun 16, 2012·PloS One·Zachary S BuchwaldRajeev Aurora
Apr 2, 2013·Autoimmunity Reviews·Theodoros DimitroulasGeorge D Kitas
May 20, 2014·Mediators of Inflammation·Patrice FardelloneVincent Goëb
Jan 26, 2016·Expert Opinion on Emerging Drugs·Francesco CasoLuisa Costa
Dec 19, 2015·Expert Review of Clinical Immunology·Maurizio CutoloCarmen Pizzorni
Jun 9, 2011·Expert Opinion on Biological Therapy·Charalampos Papagoras, Alexandros A Drosos
Jul 7, 2012·Reumatología clinica·Emilio Martín MolaUNKNOWN Spanish expert panel of rheumatologists
Jun 5, 2013·Joint, Bone, Spine : Revue Du Rhumatisme·Benoit Le GoffDominique Heymann
May 11, 2012·Joint, Bone, Spine : Revue Du Rhumatisme·Thao PhamJean Sibilia
Jan 24, 2012·Best Practice & Research. Clinical Rheumatology·Hans Ulrich Scherer, Gerd-Rüdiger Burmester
Nov 23, 2011·Reumatología clinica·Gabriel Herrero-BeaumontSantos Castañeda
Sep 1, 2009·Bone·Charles A O'Brien
Dec 6, 2008·Molecular and Cellular Endocrinology·Julian M W Quinn, Hasnawati Saleh
May 6, 2008·Best Practice & Research. Clinical Rheumatology·Daniëlle M Gerlag, Paul P Tak
Jul 11, 2008·Immunological Reviews·Kenneth J Scalapino, David I Daikh
Sep 30, 2008·Arthritis and Rheumatism·Georg SchettBernhard Manger
Apr 24, 2014·Arthritis & Rheumatology·Susanne Roser-PageM Neale Weitzmann
Aug 21, 2015·Arthritis Research & Therapy·Diahann T S L JansenRené E M Toes
Jul 11, 2014·Trends in Molecular Medicine·Julia F Charles, Antonios O Aliprantis
Aug 13, 2013·Clinical & Developmental Immunology·Giorgio MoriGiacomina Brunetti

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.